Clinical trial
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 21, 2024
- Completion date
- September 8, 2026
- Enrollment
- 1,456 (actual)
- Sites
- 235
Conditions
As the registry lists them; a condition with its own page is linked.